Erdoes L S, Berman S S, Bernhard V M, Mulcahy M, Hunter G C
Section of Vascular Surgery, University of Arizona Health Sciences Center, Tucson 85724, USA.
Ann Vasc Surg. 1995 Sep;9(5):441-7. doi: 10.1007/BF02143857.
A new stretch polytetrafluoroethylene (PTFE) aortic graft became available for clinical use in early 1991. We prospectively evaluated our first 107 stretch aortic PTFE grafts by means of serial CT imaging and compared them with a cohort of concurrently placed Dacron grafts. Stretch PTFE requires no preclotting and is claimed to resist long-term dilation and conform well to anastomoses. Consecutive patients undergoing placement of stretch PTFE grafts were seen at least yearly. Within the first 2 years after implantation, contrast-enhanced CT scans of the abdomen and pelvis were obtained. Caliper measurements were made of the native arteries and the body and any limbs of the aortic grafts. Graft elongation was assessed by noting distortions from the normally circular or minimally ovoid configuration of the grafts on transverse CT images. Indications for grafting were elective repair of abdominal aortic aneurysm in 60 patients, aortoiliac occlusive disease in 31, both aneurysm and occlusive disease in eight, and ruptured abdominal aortic aneurysm in eight. The overall operative mortality rate was 6.5%. There were two early postoperative graft limb thromboses resulting from hypercoagulable states, and there was one graft infection. Mean follow-up was 14.1 months (range 1 to 34 months). CT scans were obtained from 61 patients with stretch PTFE grafts and 10 with concomitantly placed Dacron grafts. Ten patients had two or more postoperative CT scans. Primary stretch PTFE patency was 98% and secondary patency, 100%. There was significantly less dilation of both the graft body and limbs in the stretch PTFE group (body mean 16.5%, range 6.3% to 28.1%; limb mean 19.3%, range 10% to 43%) compared to the Dacron group (body mean 33%, range 22% to 78%; limb mean 62%, range 12.5% to 88.9%) (p < 0.01, unpaired t test).(ABSTRACT TRUNCATED AT 250 WORDS)
一种新型的拉伸聚四氟乙烯(PTFE)人工血管于1991年初开始用于临床。我们通过连续CT成像对首批107例拉伸PTFE人工血管进行了前瞻性评估,并将其与同期植入的涤纶人工血管队列进行了比较。拉伸PTFE无需预凝,据称能抵抗长期扩张并能很好地贴合吻合口。接受拉伸PTFE人工血管植入的连续患者每年至少接受一次检查。在植入后的头两年内,对腹部和骨盆进行了对比增强CT扫描。对天然动脉以及人工血管的主体和任何分支进行卡尺测量。通过观察横断CT图像上人工血管偏离正常圆形或最小椭圆形形态的情况来评估人工血管的伸长。人工血管植入的指征包括60例腹主动脉瘤择期修复、31例主髂动脉闭塞性疾病、8例同时患有动脉瘤和闭塞性疾病以及8例破裂性腹主动脉瘤。总体手术死亡率为6.5%。有两例术后早期人工血管分支因高凝状态形成血栓,有一例人工血管感染。平均随访时间为14.1个月(范围1至34个月)。对61例植入拉伸PTFE人工血管的患者和10例同期植入涤纶人工血管的患者进行了CT扫描。10例患者进行了两次或更多次术后CT扫描。拉伸PTFE人工血管的一期通畅率为98%,二期通畅率为100%。与涤纶组相比,拉伸PTFE组人工血管主体和分支的扩张明显更少(主体平均扩张16.5%,范围6.3%至28.1%;分支平均扩张19.3%,范围10%至43%),而涤纶组分别为(主体平均扩张33%,范围22%至78%;分支平均扩张62%,范围12.5%至88.9%)(p<0.01,非配对t检验)。(摘要截选至250字)